Hepalatide

DRUG6 trials

Sponsors

Shanghai HEP Pharmaceutical Co., Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis D InfectionHepatitis B， ChronicHepatitis DType 2 Diabetes Patients

Phase 1

Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers

CompletedNCT02612506

Shanghai HEP Pharmaceutical Co., Ltd.Hepatitis B， Chronic

Start: 2015-10-31End: 2016-08-31Updated: 2017-02-14

Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers

CompletedNCT03023787

Shanghai HEP Pharmaceutical Co., Ltd.Hepatitis B， Chronic

Start: 2016-08-31End: 2016-12-31Updated: 2017-01-23

A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin

WithdrawnNCT04662164

Shanghai HEP Pharmaceutical Co., Ltd.Type 2 Diabetes Patients

Start: 2025-12-31End: 2025-12-31Updated: 2023-12-08

Phase 2

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

CompletedNCT05244057

Shanghai HEP Pharmaceutical Co., Ltd.Chronic Hepatitis B

Start: 2022-08-23End: 2024-06-24Updated: 2024-07-15

Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

CompletedNCT05827146

Shanghai HEP Pharmaceutical Co., Ltd.Chronic Hepatitis D Infection

Start: 2023-10-07End: 2024-02-01Updated: 2024-04-24

A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

Active, not recruitingNCT06505928

Shanghai HEP Pharmaceutical Co., Ltd.Hepatitis D

Start: 2024-12-11End: 2026-07-31Target: 90Updated: 2025-12-23